Literature DB >> 2405897

An open study of ropivacaine in extradural anaesthesia.

E Whitehead1, B Arrigoni, J Bannister.   

Abstract

Ropivacaine 0.5%, 0.75% and 1.0% was investigated in an open study of extradural anaesthesia in three groups of 15 patients undergoing urological or orthopaedic surgery. Following a test dose of 3 ml of 1.0% lignocaine with 1:200,000 adrenaline, ropivacaine 20 ml was given in incremental doses over 4 min via a lumbar extradural catheter. The onset time for analgesia was short in all groups: T12 was blocked 4-6 min after the end of the injection of ropivacaine. The maximum segmental level was significantly higher in the 0.75% and the 1.0% groups (T2) than in the 0.5% group (T5). Complete motor block was obtained in seven, four and nine patients in the 0.5%, 0.75% and the 1.0% groups, respectively. Duration of analgesia increased with increasing concentration of ropivacaine: mean duration of analgesia was 203 and 266 min at T10 and 253 and 314 min at L5 for the 0.5 and 1% solutions, respectively. Mean duration of complete motor block was 94 and 192 min for the same solutions. Analgesia was satisfactory for surgery in all patients except for one in the 0.75% group. Hypotension was experienced by three, seven and three patients in the 0.5%, 0.75% and 1.0% groups, respectively. Bradycardia occurred in seven patients and was associated with hypotension in five. Backache was experienced after operation by four patients, and three patients complained of a brief mild headache. No late adverse events were seen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405897     DOI: 10.1093/bja/64.1.67

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Anesthetic efficacy of different ropivacaine concentrations for inferior alveolar nerve block.

Authors:  Eman El-Sharrawy; John A Yagiela
Journal:  Anesth Prog       Date:  2006

Review 2.  Ropivacaine: an update of its use in regional anaesthesia.

Authors:  K J McClellan; D Faulds
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 3.  Benefit-risk assessment of ropivacaine in the management of postoperative pain.

Authors:  Wolfgang Zink; Bernhard M Graf
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Associations between single-nucleotide polymorphisms and epidural ropivacaine consumption in patients undergoing breast cancer surgery.

Authors:  Jing Liu; Yongdong Jiang; Da Pang; Hongjie Xi; Yan Liu; Wenzhi Li
Journal:  Genet Test Mol Biomarkers       Date:  2013-04-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.